Globally, the rate hike has been driven by decline in belly cargo capacity, which is leading to an increase in…
Consolidated revenue remained dropped 13.2% y-o-y Rs 18.9bn (I-Sec: Rs 23.1bn) and adjusted PAT declined 52.4% y-o-y on lower revenue…
As per media reports, Tata Motors saw highest sales since Mar’18 at ~18.6k units, up 154% y-o-y to become 3rd…
The in-principle approval by the NMDC board to demerge the steel plant, i.e. creating a separate listed company eventually with…
ACEM plans to set up WHRS plants at Darlaghat and Bhatpara (19.5MW at each location) at a capex of Rs…
Upgrade rating to ‘buy’ on Embassy REIT from ‘add’ with revised NAV of Rs 430/unit: ICICI Securities
At CMP of Rs360, the Embassy REIT offers a distribution yield of 6.8% in FY21E, 7.1% in FY22E and 7.8%…
The company’s core RoE remained strong at 19.5%, but fixed cost under- recovery was at Rs 2.3 billion (Rs 1.2…
Europe Ebitda came as a disappointment; net debt was flat q-o-q; earnings tailwind augurs well; ‘Buy’ retained; top sectoral pick
FY21-22e EPS up 22-32% due to lower depreciation and higher other income; TP raised to Rs 25,800 from Rs 22,400;…
India business expected to remain robust while the other markets are likely to recover; EPS estimates up 3-5%; TP revised…
Drivers are focus on distribution expansion and increase in direct reach, higher in-home consumption of beverages leading to market share…
Chola exuded confidence in the adequacy of its Covid/macro provisions and chose not to make additional accelerated provisions in Q1FY21.
Gross margin declined 570 bps to 41.7% due to lower franchise income, input cost inflation and one-off obsolete inventory write off.
ONGC expected to be in red; steep EPS fall likely for CGD players; GAIL, PLNG, GSPL to see more moderate…
Cement business showed better results in Q1; -18/9% change in FY21/22e Ebitda; TP up to Rs 52; ‘Add’ retained.
JK Cement’s (JKCE) recent capacity additions in high utilisation/better pricing markets of north/central regions are likely to see a quick…
FY21/22 EPS up 12.3/11.8% given results and recovery in output; TP raised to Rs 1,890
Glenmark initially received DCGI nod to conduct phase-3 clinical trials with oral antiviral Favipiravir among COVID-19 patients in early May’20…
